Royalty Pharma(RPRX) - 2024 Q1 - Quarterly Results

Capital Deployment of approximately $670 million, including cash expected to be paid for frexalimab Development-stage portfolio growing to 15 therapies with potential significantly >$1 billion in peak royalties Financial guidance for full year 2024 (excludes contribution from future transactions) Exhibit 99.1 ROYALTY PHARMA REPORTS FIRST QUARTER 2024 RESULTS NEW YORK, NY, May 9, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 20 ...